Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Jeffrey Skolnik,VP-Inovio-Pharmaceuticals,2nd Annual Glioblastoma-Drug-Development-Summit-12/9-10

Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead in oncology at GSK and held several positions at AstraZeneca including Senior Director for both early and late stage compounds. Dr. Skolnik is also a practicing pediatric Hematologist-Oncologist, and has published several papers regarding pediatric oncology trial design.

Day One
Wednesday, December 09, 2020

6:05 pm | PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets

• Examine the current treatment options and emerging targeted therapies
• If targeted therapies show limited efficacy as single agents, can the combination of several targeted
therapies be of benefit to GBM patients?
• Additional research is urgently required to identify therapeutic targets in GBM: How can the industry
design novel therapeutic strategies for the treatment of GBM?

3:05 pm | Empower the Immune System to Treat Glioblastoma: DNA as Medicine

• Explore DNA medicines that have the potential to create robust, antigen-specific T cell responses
• Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in GBM showing early efficacy, and immunogenicity
• Discuss Inovio’s DNA medicine, its technology, and other promising approaches to GBM therapy will be discussed

Day Two
Thursday, December 10, 2020

5:35 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

• Debate the common challenges with moving GBM clinical trials forward
• What can we learn from the plethora of failed phase 2 trials?
• With a high failure rate of phase 3 glioblastoma trials, panellists examine the need for greater reliability
of earlier studies

David Reardon
Clinical Director, Center for NeuroOncology
Dana-Farber Cancer Institute
Day One
Wednesday, December 09, 2020

11:40 am | An Exclusive Update on Neoantigen Vaccination for Glioblastoma

• Describe rationale for targeting neoantigens for anti-tumor vaccination
• Summarize therapeutic development of neoantigen vaccination for
oncology to date
• Overview results of neoantigen vaccination application for glioblastoma
• Enhance next steps to optimize neoantigen vaccination for glioblastoma

Day Two
Thursday, December 10, 2020

5:35 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

https://glioblastoma-drugdevelopment.com/about/speakers/